Altimmune Inc Total Assets
Altimmune Inc total assets. Based on the latest financial reports, Altimmune Inc (ALT) holds total assets worth $279.93 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Altimmune Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Altimmune Inc (2005–2025)
Total assets of Altimmune Inc from 2005 to 2025. This chart illustrates how Altimmune Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Altimmune Inc for real-time trading data and today's change.
Altimmune Inc - Asset Composition Analysis
Altimmune Inc Total Assets Breakdown (December 2025)
Altimmune Inc total assets breakdown as of December 2025. Altimmune Inc's total assets of $279.93 Million consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.6% |
| Accounts Receivable | $1.74 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Altimmune Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ALT current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Altimmune Inc's current assets represent 99.4% of total assets in 2025, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2025, up from 2.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Altimmune Inc Competitors by Total Assets
Key competitors of Altimmune Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Altimmune Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.55 | 13.11 | 24.96 |
| Quick Ratio | 18.55 | 13.11 | 24.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $263.19 Million | $126.79 Million | $235.37 Million |
Altimmune Inc - Advanced Valuation Insights
This section examines the relationship between Altimmune Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.12 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | 100.9% |
| Total Assets | $279.93 Million |
| Market Capitalization | $265.49 Million USD |
Valuation Analysis
Near Book Valuation: The market values Altimmune Inc's assets close to their book value (0.95x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Altimmune Inc's assets grew by 100.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Altimmune Inc (2005–2025)
The table below shows the annual total assets of Altimmune Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $279.93 Million | +100.95% |
| 2024-12-31 | $139.31 Million | -33.87% |
| 2023-12-31 | $210.64 Million | +1.79% |
| 2022-12-31 | $206.93 Million | -5.45% |
| 2021-12-31 | $218.86 Million | -10.71% |
| 2020-12-31 | $245.12 Million | +353.43% |
| 2019-12-31 | $54.06 Million | -1.26% |
| 2018-12-31 | $54.75 Million | -13.14% |
| 2017-12-31 | $63.03 Million | -71.95% |
| 2016-12-31 | $224.74 Million | +1031.48% |
| 2015-12-31 | $19.86 Million | -9.63% |
| 2014-12-31 | $21.98 Million | +28.23% |
| 2013-12-31 | $17.14 Million | -24.63% |
| 2012-12-31 | $22.74 Million | -0.27% |
| 2011-12-31 | $22.80 Million | -16.16% |
| 2010-12-31 | $27.20 Million | -20.16% |
| 2009-12-31 | $34.07 Million | -39.59% |
| 2008-12-31 | $56.39 Million | -15.34% |
| 2007-12-31 | $66.61 Million | -7.15% |
| 2006-12-31 | $71.74 Million | +2.36% |
| 2005-12-31 | $70.09 Million | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.